Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

25.81 +1.41 (+5.78%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	240,872
Open	24.45
Bid (Size)	22.00 (100)
Ask (Size)	26.50 (1,500)
Prev. Close	24.40
Today's Range	24.42 - 26.49
52wk Range	18.35 - 39.92
Shares Outstanding	11,782,723
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Royalty to Present at Investor Conferences in March

February 18, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

February 09, 2026

Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right

From XOMA Royalty Corporation

Via GlobeNewswire

Performance

YTD	-7.8%	-7.8%
1 Month	-1.1%	-1.1%
3 Month	-18.9%	-18.9%
6 Month	-21.2%	-21.2%
1 Year	+3.0%	+3.0%

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗

September 30, 2025

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

XOMA Royalty Announces CFO Transition

January 12, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

Unusual volume stocks in Wednesday's session ↗

January 07, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

December 30, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

December 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Enters into Agreement to Acquire Generation Bio

December 15, 2025

From Generation Bio Co.; XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)

December 13, 2025

Via PredictStreet

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

December 05, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

December 05, 2025

From Mural Oncology plc

Via GlobeNewswire

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

November 26, 2025

From Mural Oncology plc

Via GlobeNewswire

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

October 24, 2025

From Mural Oncology plc

Via GlobeNewswire

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗

October 17, 2025

Via Stocktwits

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality

October 17, 2025

Via MarketMinute

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Common Stock publicly traded?

Yes, XOMA Royalty Corporation - Common Stock is publicly traded.

What exchange does XOMA Royalty Corporation - Common Stock trade on?

XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for XOMA Royalty Corporation - Common Stock?

The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market

What is the current price of XOMA Royalty Corporation - Common Stock?

The current price of XOMA Royalty Corporation - Common Stock is 25.81

When was XOMA Royalty Corporation - Common Stock last traded?

The last trade of XOMA Royalty Corporation - Common Stock was at 02/20/26 04:00 PM ET

What is the market capitalization of XOMA Royalty Corporation - Common Stock?

The market capitalization of XOMA Royalty Corporation - Common Stock is 304.11M

How many shares of XOMA Royalty Corporation - Common Stock are outstanding?

XOMA Royalty Corporation - Common Stock has 304M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.